This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the full mainstage presentations please see: https://youtu.be/v85bJi-vtGM For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.
Author: admin
By: Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, Date: 11/03/2023 Courtesy: VJOncology Above is a video from Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea about the MARIPOSA Phase 3 trial a randomized study comparing amivantamab plus lazertinib compared to osimertinib in advanced EGFR mutated lung cancer. During this ESMO 2023, the primary and some secondary endpoints of the MARIPOSA study were presented. The primary endpoint of the MARIPOSA study aimed to evaluate the progression-free survival (PFS) of amivantamab plus lazertinib compared to osimertinib according to RECIST version 1.1. The secondary endpoints included overall survival, duration of…
By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer.The study aimed to address resistance to CDK4/6 inhibitors in this specific patient subset. McIntosh’s research sought to explore the benefits of this combination therapy, focusing on efficacy, safety, and tolerability.The investigation explored the risks and benefits linked with the combination therapy. Early findings indicated potential therapeutic advantages in managing resistance in this…
By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly for HLA-A02:01 positive patients with the introduction of tebentafusp (TA BENT A FUSP). In comparison to the control group, tebentafusp demonstrated notable improvements in overall survival rates. The specific data revealed a substantial increase in survival rates among patients receiving tebentafusp compared to those in the control group. This has a significant impact on the current standard of care for HLA-A02:01 positive patients, potentially reshaping treatment protocols for this subgroup.Regarding early survival benefits, the first six weeks of tebentafusp treatment…
By. Corina Dutcus, MDDate. November 02, 2023Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic esophageal squamous cell carcinoma, presented insights into the trial’s objectives, findings, and implications for patient care.The Phase 3 LEAP-014 trial aimed to evaluate the efficacy and safety of combining lenvatinib, pembrolizumab, and chemotherapy for this cancer type, focusing on overall survival, progression-free survival, and safety measures.Dr. Dutcus summarized the trial findings, noting improvements in overall survival, progression-free survival, and a manageable safety profile for the combination therapy.The addition of lenvatinib and pembrolizumab to chemotherapy represents a significant advancement in the…
By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact on cancer cells and its potential significance in treating metastatic castration-resistant prostate cancer and thoracic malignancies.Addressing the significance of PT-112’s ability to release damage-associated molecular patterns (DAMPs) and induce immunogenic cell death (ICD), Dr. Ames underscores their pivotal role in the immune system’s response against cancer. The release of DAMPs triggers an immune response, alerting the body to recognize and target cancerous cells, particularly crucial in metastatic and castration-resistant prostate cancer and thoracic malignancies.When exploring the early molecular effects of…
By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into the NATALEE trial, presenting pivotal data at ESMO 2023. The trial, under his leadership, aimed to advance breast cancer therapy and contribute significantly to understanding treatment modalities. Dr. Bardia’s contributions to the trial and subsequent findings established him as a prominent figure in advancing breast cancer research. The NATALEE trial had specific objectives, focusing on improving outcomes for patients with HER2-positive early breast cancer. It investigated the effectiveness of dual HER2 blockade (using two anti-HER2 agents) in combination with chemotherapy…
By. Corina Dutcus, MDDate. November 01, 2023Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development at Eisai, recently addressed critical aspects of the Phase 3 Study 309/KEYNOTE-775 trial focusing on patients with advanced endometrial cancer. The trial specifically evaluated the efficacy of pembrolizumab in combination with lenvatinib for patients who had undergone prior platinum therapy.During the interview, Dr. Ductus discussed the key findings from the trial. The research showcased significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). These statistically and clinically significant enhancements in patient outcomes hold immense significance…
Author: Dr Antonio Passaro (on-camera comments) – Courtesy of ESMO.org At the ESMO 2023 conference, the results of the Phase three global randomized Mariposa 2 trial were presented. The trial focused on patients with advanced non-small cell lung cancer after progressing on Ozimertinib due to an EGFR mutation. The study aimed to evaluate Amivantamab combined with chemotherapy, with or without Lazertinib, compared to standard chemotherapy. The trial involved 657 patients from various regions and aimed to assess progression-free survival. The primary endpoint was to compare the survival benefits among the different treatment arms. The study found a statistically significant improvement in…
Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort, aims to determine the efficacy of a triplet regimen involving chemotherapy with flood alongside durvalumab in treating early-stage non-metastatic gastric and gastroesophageal adenocarcinoma. Presented at ESMO 2023, the study’s first interim analysis involved nearly 1000 patients from various regions globally, utilizing a randomized approach of flood plus durvalumab or placebo. Results revealed a 12% enhancement in complete response rate and a 15% improvement in node negativity status, which is crucial for clinical outcomes. While the study successfully met its interim…
By. Antonio Passaro, MDDate. October 31, 2023Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.The study’s key findings have been groundbreaking, revealing a significant advancement in the treatment landscape for NSCLC. Dr. Passaro highlights the remarkable results that demonstrate a 56% and 52% reduction in the risk…
By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key figure in understanding the clinical significance of HPN328, a cutting-edge immunotherapy drug. Her expertise and experience in the field enable a comprehensive analysis of recent clinical trial data and its implications for cancer treatment.In the interview, Dr. Noura Choudhury addresses the significant insights drawn from HPN328’s clinical trial results. Highlighting the drug’s remarkable confirmed response rate of 35% across diverse tumor types with a mere 1 mg priming dose, including instances of complete responses, she elucidates the potential implications for…
By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD Anderson Cancer Center, is slated to share his expertise during an exclusive interview. The discussion will revolve around pivotal inquiries concerning TIGIT and its implications in immunotherapy.The interview will provide a comprehensive exploration of various critical facets related to TIGIT. Dr. Derbala will delve into the intricate role that TIGIT plays in immune suppression, shedding light on its function as an inhibitory receptor impacting immune cells such as T cells and natural killer (NK) cells. His extensive research and findings…
By. Corina Dutcus, MDDate. October 30, 2023In this video interview, Corina Dutcus, MD, will address pivotal aspects of phase 3 CLEAR study, focusing on the combination of lenvatinib and pembrolizumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC). She will dive into the key findings and their implications for clinical practice.Dr. Dutcus will highlight the study’s pivotal results, emphasizing the better objective response rate (ORR) achieved with the lenvatinib and pembrolizumab combination compared to sunitinib. She will explain the significance of ORR in this context, elucidating its role as a metric in evaluating treatment efficacy.Furthermore, the discussion…
Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment for metastatic or irresectable urothelial cancer patients, aimed to improve existing chemotherapy approaches. Traditionally, chemotherapy, primarily cisplatin or gemcitabine, has been the standard for such cases. With the recent introduction of immunotherapy, there has been a challenge as many patients were unable to transition to immunotherapy post-chemotherapy. Involving around 600 patients, the study randomized participants into two groups: one receiving the standard cisplatin-gemcitabine and the other receiving this combination along with nivolumab, a checkpoint inhibitor. The trial successfully met its…
Dr Laurence Albiges (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, an individual presented a study at the forefront of oncology research. The study, known as LITESPARK-005, focused on patients with advanced kidney cancer who had previously undergone unsuccessful therapy. The trial explored the effectiveness of Belzutifan, a first-in-class inhibitor, in treating clear cell renal cell carcinoma (RCC) by targeting the hypoxia-inducible factor. This inhibitor, Belzutifan, works by impeding the dimerization of IF 2A, thereby blocking the downstream oncogenic pathway. The study enrolled over 700 patients and demonstrated positive outcomes. Primary results showed a significant increase in progression-free survival…
Author: Dr Herbert Ho Fung Loong (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, I’ve had the pleasure of presenting our groups data which is the Libretto 431 study which is actually a first line study of the use of supper catching it versus standard chemotherapy plus pembrolizumab in patients with newly diagnosed red fusion positive non small cell lung cancer. So by way of background red fusion accounts for about 2% of all non small cell lung cancers. And previously at least prior to the knowledge of knowing the fact that RET as a driver for most of these…
Author: Dr. Oliver Sartor (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, an opportunity arose to present new data from the [177Lu]Lu-PSMA-617 trial, which focused on metastatic KR-resistant prostate cancer in treatment-naive patients. The study compared two agents from different classes: IS lithium and a secondary hormone (either abiraterone or insulin). Eligibility for the study was determined through PSMA PET scans, which revealed that 92% of patients were qualified. A total of 468 patients were randomized, with the primary endpoint being radiographic progression-free survival (rpfs). The data presented at ESMO showed a significantly positive outcome, with an rpfs Hazard…
Author: Professor Ben Solomon (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, the speaker had the pleasure of presenting the findings from the global phase 3 Alina study. This study marked the first randomized investigation of aninhibitor in patients with entirely resected ALK-positive non-small cell lung cancer. The presentation highlighted the high recurrence rates after surgery in this patient population and emphasized that the advances seen in early-stage immunotherapy didn’t apply here. The standard of care still revolved around Adan Platinum-based chemotherapy. In the Alina study, the effects of two years of LBA2 – ALINA treatment on disease-free survival after…
Author: Dr. Domenica Lorusso (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, the results of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial were presented. This trial marked the first evaluation of Pembrolizumab immunotherapy in combination with chemoradiation for locally advanced high-risk cervical cancer since 1999. Historically, the treatment for such patients involved concomitant chemoradiation followed by brachytherapy. However, this trial aimed to demonstrate an improvement in progression-free and overall survival when combining immunotherapy with chemoradiation. A total of 160 patients were enrolled and randomized into two groups: one receiving concomitant chemoradiation followed by brachytherapy with a placebo, and the other receiving the same…
By. Shannon Westin, MDDate. October 27, 2023In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E Phase III trial, focusing on the combination of IMFINZI® (durvalumab) and LYNPARZA® (olaparib) in advanced or recurrent endometrial cancer and its implications for patient treatment options.Dr. Shannon Westin highlights the significant impact of the DUO-E Phase III trial findings on the management of advanced or recurrent endometrial cancer. She emphasizes that the combination of IMFINZI® and LYNPARZA® showed a remarkable 45% reduction in the risk of disease progression or death when compared to chemotherapy in the overall trial population. This…
By. Brian SlomovitzDate. October 26, 2023 Brian Slomovitz, MD, presented insights into the innovaTV 301 study and its implications for patients dealing with the condition. Within the innovaTV 301 study, crucial findings emerged for cervical cancer patients, showcasing advancements in overall survival, progression-free survival, and objective response rate. These outcomes held significant value for the patients. Specifically, the study highlighted how tisotumab vedotin (TV) extended both the overall and progression-free survival compared to standard chemotherapy. This meant an extended life expectancy and delayed disease progression for patients treated with TV. While the objective response rate was lower than observed in…
By. Neil Gross, MDDate. October 26, 2023 In a discussion detailing the primary outcomes of the Phase 2 trial for Libtayo as a neoadjuvant therapy for Cutaneous Squamous Cell Carcinoma (CSCC), Dr. Neil Gross presented critical aspects related to the study. The trial, incorporating the use of Libtayo, a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc., aimed to assess its effectiveness as a neoadjuvant monotherapy in stage II to IV resectable CSCC. This trial marked a significant milestone in oncology and was showcased at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology.…
By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore serves as a key figure in elucidating the trial’s primary objective. The primary aim of this clinical trial is to assess the safety and efficacy of the combination therapy involving enzalutamide and leuprolide in patients with high-risk biochemical recurrence of prostate cancer.The patient group identified as “high-risk for biochemical recurrence” in this trial comprises individuals who have previously undergone primary treatment for prostate cancer and subsequently experienced a rise in prostate-specific antigen (PSA) levels. These patients are at greater risk…
By: Loren Michel, MD Date: October 25, 2023 At the recent ESMO conference, Dr. Loren Michel presented the results of the TROPiCS-03 clinical trial, which investigated the use of sacituzumab govitecan (SG) in advanced head and neck cancer. The primary and key secondary endpoints in this study held significant importance in assessing SG’s effectiveness in patients with advanced HNSCC. The primary endpoint was the objective response rate (ORR), which stood at 16%. The ORR represents the proportion of patients who exhibited a meaningful tumor response to SG, indicating its potential to shrink or stabilize tumors. The key secondary endpoint, the…
By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator of the EV-302 phase 3 trial, where the discussion revolved around the Enfortumab Vedotin and Pembrolizumab combination and its potential impact on bladder cancer treatment. During the interview, Dr. Powles detailed how the Enfortumab Vedotin-Pembrolizumab combination displayed a 53% reduction in the risk of death in comparison to conventional chemotherapy for bladder cancer patients. The conversation explored the factors contributing to the extended median overall survival of 31.5 months for patients on the combination regimen, a significant improvement over the…
By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands at the forefront of groundbreaking clinical trials. Her work on the GMMG-CONCEPT trial, involving Isatuximab combination therapy, has unveiled a pivotal shift in the treatment landscape for high-risk multiple myeloma patients. Achieving sustained minimal residual disease (MRD) negativity is a remarkable feat in the context of this complex blood cancer. MRD negativity implies that there is an exceedingly low level of cancer cells remaining in a patient’s system. In high-risk multiple myeloma, the significance of this achievement cannot be overstated.…
By: Abdulraheem Yacoub MD Date: October 25, 2023 In a prestigious medical conference hall filled with experts in the field of hematological cancers, Abdulraheem Yacoub MD took the stage to address the attentive audience. He commenced his speech with gratitude, saying, “Thank you, Lucia. It’s my pleasure now to invite Abia Kube, who runs what I call an MPN Empire in the middle of the country, and is leading the Limber phase three study in the front line and has also done some great work with the consortium. Thanks, Abe. Good afternoon.” Dr. Yacoub’s appreciation extended further as he continued, acknowledging the…
Canonical URLs
By: Elizabeth Brem, MD Date: October 06, 2023 Elizabeth Brem, MD, began her talk by addressing some disclosures she had omitted in her previous presentation. She then stressed the importance of intergroup studies, particularly for rare populations like PTCL and HL. She highlighted their unique ability to establish real comparator arms, citing examples from CLL trials. Moving on to specific studies, Dr. Brem emphasized the groundbreaking nature of “eighteen twenty six” in Hodgkin lymphoma, describing it as a study poised to change the standard of care in a way that no other mechanism could achieve. She also discussed the potential…
By: John Mascarenhas, MD Date: October 04, 2023 John Mascarenhas, MD, stands as a distinguished authority in the realm of myelofibrosis treatment. Drawing upon his extensive expertise and experience, Dr. Mascarenhas delivered an enlightening presentation in 2023, shedding light on the drugs Pacritinib and Mamelotnib. During his presentation, he underscored the critical importance of comprehending the distinct properties and profiles of these two JAK inhibitors. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…
By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: “Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, another challenging lymphoma. These are my disclosures.” She went on to provide valuable insights into mantle cell lymphoma, emphasizing its prevalence, gender distribution, and the often advanced stage at which patients are diagnosed. Julie stated, “Mantle cell lymphoma, not the most common lymphoma, about sixty nine percent, and patients…
Preventing a Carboplatin Shortage: Strategies to Ensure Cancer Drug Availability in 2023 In an era where advancements in cancer treatment are making great strides, the looming threat of a carboplatin shortage casts a shadow over these achievements. Carboplatin, a critical chemotherapy drug, is essential for treating various forms of cancer. However, recent shortages have disrupted patient care and left healthcare providers scrambling for solutions. What are the consequences of these carboplatin shortages, and how can we address them to ensure that cancer patients receive the life-saving treatments they need? Key Takeaways Carboplatin shortage has caused disruptions in cancer treatment, necessitating…
Harnessing the Power of Dostarlimab to Treat Advanced or Recurrent Endometrial Cancer Endometrial cancer remains a significant challenge for medical oncology. However, recent advances in cancer treatment have brought a new hope for patients with advanced or recurrent endometrial cancer: Dostarlimab. How does this innovative immunotherapy work, and what does it mean for patients with this challenging disease? Read on to discover the breakthroughs of the RUBY trial and the potential impact of Dostarlimab on endometrial cancer treatment. Key Takeaways Dostarlimab (Jemperli) is an innovative immunotherapy approved by the FDA for advanced or recurrent endometrial cancer. The RUBY trial revealed…
GeoVax, a pioneering healthcare company, has developed a groundbreaking product known as GADEPTIN. GADEPTIN is a cutting-edge therapy designed to target and treat the initial indications of advanced head and neck cancer, with the potential to address various solid tumors as well. The mechanism behind this innovative treatment involves the use of an enzyme, the PNP enzyme, which is delivered into the tumor through an established adenovirus vaccine.The treatment process begins by administering the PNP enzyme directly into the targeted tumor. Most tumors are accessible with a needle, making this a precise and localized delivery method. Following the introduction of…
By: Allen WilbanksDate: October 01, 2023 In a conference room filled with medical professionals and researchers, the audience leaned forward, eager to hear the insights of the esteemed Raajit Rampal, MD. As he took the stage, he couldn’t help but make a light-hearted comment about the outdated slides he was presented with. “That’s an outdated slide,” Dr. Rampal remarked with a chuckle. “The Abe is now a full professor.” His comment drew a few laughs from the audience, setting a relaxed tone for the presentation. Dr. Rampal then introduced his collaborator, Doctor Ramal, with warm praise. “And now from the…
By: Allen WilbanksDate: October 02, 2023 In a comprehensive discussion led by the esteemed Swami Lyer, MD, the focus centered on the evolving landscape of therapies for T-cell lymphomas. Dr. Lyer commenced the talk with expressions of gratitude, acknowledging the invaluable contributions of patients participating in clinical studies. The central theme revolved around elucidating the prospects of late and forthcoming treatments in T cell lymphomas, with an emphasis on the pivotal role of transplantation. One of the primary challenges in managing T cell lymphomas is the intricate classification system. Dr. Lyer illustrated the complexity by highlighting the multitude of subtypes…
By: Allen Wilbanks Date: September 29, 2023 In the groundbreaking Phase 3 LUNAR study led by Dr. Ticiana Leal, MD, and her esteemed colleagues, a discovery with the potential to revolutionize the management of metastatic non-small-cell lung cancer (NSCLC) has emerged. This study focused on patients who had experienced disease progression following platinum-based therapy, a group often faced with limited treatment options. The primary objective of the study was to assess the efficacy and safety of TTFields therapy when combined with standard systemic therapy. The results of this study were nothing short of remarkable. Dr. Leal stated, “The randomized, pivotal…
Allen Wilbanks asked Ticiana Leal, MD from the Winship Cancer Institute of Emory University, about her thoughts on the overall impact of TTFields treatment on the lives of patients with lung cancer.Ticiana Leal, MD, shared her perspective, emphasizing the challenges posed by lung cancer and the potential benefits of TTFields treatment for patients, particularly in the second line and beyond. She highlighted that this treatment offers an opportunity to improve survival without introducing additional systemic toxicities or compromising the quality of life.Watch the full interview here
Ticiana Leal, MD, a distinguished oncologist from the Winship Cancer Institute of Emory University, shared her insights during a discussion on the use of Electric Field (ED) therapy for lung cancer, addressing the ongoing challenges and areas for future research. In response to a question posed by Allen Wilbanks, Dr. Leal remarked, “Yeah, I think we’re going to continue to investigate the use of TT fields in non-small cell lung cancer.”With a poised demeanor, Dr. Leal highlighted the importance of comprehending how to integrate TT (Tumor Treating) fields into the existing landscape of systemic therapies. She emphasized this need, not…
By: Allen Wilbanks Date: September 29/2023 At the conference, Pankit expressed gratitude for another great talk, saying, “Thank you, Pankit for another fantastic talk. It’s my honor now to introduce Laura Michaelis, MD, a leader in myeloid malignancies at ASH and SWAG. Thank you, Laura.” Laura Michaelis began her presentation by acknowledging her pleasure to be there and shared two important lessons learned so far – the value of presentation slides and the need for humor. She then delved into essential thrombocythemia, emphasizing the critical importance of accurate diagnosis before treatment. Dr. Michaelis highlighted the significance of thorough diagnostics, especially…
In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed the findings from the NATALEE trial, focusing on the role of ribociclib in reducing the risk of cancer recurrence in early breast cancer patients while maintaining their quality of life. Dr. Fasching explained that ribociclib is a CDK4/6 inhibitor that can halt the cell cycle and send cells into senescence, making it a promising treatment option for early breast cancer patients.The Natalie trial, which involved over 5,000 patients, revealed that adding ribociclib to standard endocrine treatment resulted in a significant…
AVEO Oncology Fotivda Video Pre-Roll
In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised an important question. Ticiana Leal, MD, an esteemed expert from the Winship Cancer Institute of Emory University, provided valuable insights into this topic.Dr. Leal began by highlighting the extensive experience with TT field treatment in patients with glioblastoma. She noted that real-world results for glioblastoma patients have consistently shown efficacy, safety, and improved quality of life, aligning with the landmark trials that led to the approval of TT fields in conjunction with temozolomide.Transitioning to non-small cell lung cancer, Dr. Leal…
In a recent discussion, Ticiana Leal, MD, sheds light on TD Fields treatment for non-small cell lung cancer. This innovative approach offers a unique localized therapy with potential systemic immune effects. However, Dr. Leal emphasizes that it doesn’t replace traditional treatments but complements them. She hints at exciting synergy possibilities when combined with systemic therapies. To learn more, watch the video for a deeper understanding of this groundbreaking approach.Watch the full interview with Ticiana Leal, MD here.
By: Allen Wilbanks Date: September 28/2023 Paolo Strati, MD, an assistant professor at the Anderson Cancer Center in Houston, Texas, delivered a comprehensive presentation on bispecific antibodies and their comparison to CAR T-cell therapy for patients with diffuse large B-cell lymphoma and follicular lymphoma. Dr. Strati emphasized the importance of collaboration in the field and discussed the development of bispecific antibodies, highlighting their journey from single-chain variable fragments to FDA approval. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…
By: Allen Wilbanks Date: September 28, 2023 Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect. He mentioned, “We’ll have Rajith talking about Jack one, whether inhibiting it is a good thing or not so much, and what exactly it means in our patients.” He then introduced Steve O, who would delve into Nf Kappa b and present his much-talked-about ACVR research from the last ASH meeting. Rampal introduced the esteemed speakers, acknowledging Steve O from Washu and himself, Raajit Ramal from Stone Kettering. With a playful tone, he acknowledged the potential for missteps, saying, “So…
By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr. Flowers for the opportunity. She discussed innovative approaches for relapse refractory Hodgkin lymphoma. Dr. Kambhampati outlined her talk, covering BV and PD-1 inhibitors as salvage treatments, novel combinations, emerging immunotherapies, targeted treatments, and the role of stem cell transplants. Standard treatment involves salvage chemotherapy and autologous stem cell transplant, with room for improvement in response rates. BV and PD-1 inhibitors are increasingly used in earlier treatment lines, showing high response rates. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…